Seattle-area health data startup Truveta announced a collaboration Tuesday with Boston Scientific, a leading medical device company. The partnership will enable Boston Scientific researchers to access Truveta’s de-identified data from more than 65 million U.S. patients, with the aim of gathering insights into devices and disease states. To show the value of its approach, Truveta also released a preliminary analysis of peripheral artery disease linking various treatments and devices with outcomes. Truveta also recently released an overview of its findings on COVID-19, and added four new health systems to its network, bringing the total to 24. Terms of the deal with Boston Scientific were not disclosed.